All: Brain, nervous system
REDEFINE AYAO: Reducing Emotional Distress, Enhancing Function and Improving Network Engagement in Adolescent and Young Adult Oncology
The purpose of this study is to test an 8-week stress reduction course that is intended to reduce anxiety and improve the quality of life of adolescents and young adults diagnosed with cancer. This study will include a total of 100 participants, all of whom have been diagnosed with cancer.
Principal Investigator: Victorson
Phase Ib/II multicenter study of buparlisib plus carboplatin or lomustine in patients with recurrent glioblastoma multiforme (GBM)
There are two purposes for this study. The purpose of the first phase of this study is to determine the highest safe dose of buparlisib given in combination with carboplatin or with lomustine in people with recurrent glioblastoma. The purpose of the second phase of this study is to determine whether, buparlisib given in combination with carboplatin and buparlisib given in combination with lomustine compared to lomustine alone, is effective and safe for patients in recurrent glioblastoma.
An Open Label Phase 1b/2 Study of Orally Administered PLX3397 in Combination with Radiation Therapy and Temozolomide in Patients With Newly Diagnosed Glioblastoma
The purpose of this research study is to assess the safety and efficacy of PLX3397 (the study drug) in people diagnosed with a type of brain cancer called gliblastoma multiforme (GBM).
A Phase 1b/2, Open-label Study to Evaluate the Safety and Tolerability of MEDI6469 in Combination with Immune Therapeutic Agents or Therapeutic Monoclonal Antibodies in Subjects with Selected Advanced Solid Tumors or Aggressive B-cell Lymphomas
The main purpose of this study is to determine the best dose of MEDI6469 that is safe and tolerable when given alone or in combination with tremelimumab, MEDI4736, or rituximab in subjects with either advanced solid tumors or diffuse large B-cell lymphoma (DLBCL).
Status: Accepting New Patients
Principal Investigator: Chae
Phase I/Comparative Randomized Phase II Trial of TRC105 plus Bevacizumab versus Bevacizumab in Bevacizumab-Naïve Patients with Recurrent Glioblastoma Multiforme
The purpose of this study is to compare any good and bad effects of using a combination of the chemotherapy drug, TRC105, with the usual approach chemotherapy drug, bevacizumab to using the usual approach bevacizumab drug alone.
Phase 2 Dose-Escalation Study of TPI 287 in Combination with Bevacizumab in Adults with Recurrent or Progressive Glioblastoma Following a Bevacizumab-Containing Regimen
The purpose of this research study is to test an experimental (not approved by the Food and Drug Administration or “FDA”) drug called TPI 287 in combination with an FDA approved drug called bevacizumab, which is also known as Avastin.
Randomized Phase II of Concurrent Bevacizumab & Re-Irradiation Versus Bevacizumab Alone as Treatment for Recurrent Glioblastoma
The purpose of this study is to determine whether adding radiation to bevacizumab is more effective in treating recurrent (cancer that has returned after treatment) glioblastoma than using bevacizumab alone.
A Phase II Trial of Oral Pazopanib plus Oral Topotecan Metronomic Antiangiogenic Therapy for Recurrent Glioblastoma Multiforme (A) without Prior Bevacizumab Exposure and (B) after Failing Prior Bevacizumab
The goal of this clinical research study is to learn if pazopanib when given in combination with topotecan can help to control glioblastoma. The safety of this drug combination will also be studied.
A Phase 1/2 Study of SL-701, a Subcutaneously Injected Multivalent Glioma-Associated Antigen Vaccine, in Adult Patients with Recurrent Glioblastoma Multiforme
The goal of this research study is to find out if SL-701 is safe and tolerable and what effect it has on brain tumors.
A Phase 2, Multicenter, Open-Label Study Of BGJ398 in Patients with Recurrent Resectable or Unresectable Glioblastoma
The main purpose of this study is to find out if BGJ398 is safe and if it is effective in treating glioblastoma.
Extended Duration Varenicline for Smoking among Cancer Patients: A Clinical Trial
The main purpose of this research study is to compare 12 versus 24 weeks of varenicline treatment, also known as Chantix®, for smoking cessation.
Status: Accepting New Patients
Principal Investigator: Hitsman
Phase II Randomized Study of Rituximab, Methotrexate, Procarbazine, Vincristine & Cytarabine with and without Low-Dose Whole-Brain Radiotherapy for Primary Central Nervous System Lymphoma
This is a randomized investigational study is to determine the effects, good and/or bad, of the combination of low-dose whole brain radiation plus chemotherapy on PCNSL (Primary Central Nervous System Lymphoma) and tumor versus chemotherapy alone.
A Phase II Study of the Efficacy of Hypofractionated Radiation Therapy with Bevacizumab and Temozolomide Followed by Maintenance Temozolomide and Bevacizumab for Recurrent High-Grade Gliomas
The purpose of this study is to determine the effectiveness and safety of combining multiple types of treatments for patients who have recurrent high grade brain tumors.
Phase I/II Adaptive Randomized Trial of Bevacizumab versus Bevacizumab plus Vorinostat in Adults with Recurrent Glioblastoma (BTTC11-02)
The purpose of this study is to learn if bevacizumab when given with or without vorinostat can help to control malignant gliomas. The safety of these drug combinations will also be studied.
A Phase I-II trial Everolimus and Sorafenib in Patients with Recurrent High-Grade Gliomas BTTC09-01
This study has two phases. In Phase I, the purpose of this study is to determine the highest safe dose and best schedule for the combination of the study drugs, everolimus and sorafenib, for malignant glioma. In Phase II, the purpose is to evaluate the effect of these drugs on malignant gliomas.
A Phase 1 Study Evaluating the Safety and Pharmacokinetics of ABT-414 in Combination with Radiation Plus Temozolomide or Temozolomide Alone for Subjects with Glioblastoma Multiforme
The purpose of this study is to study the safety of the study drug (ABT-414), to find highest safe dose of the study drug, and to study how a patient's body handles this new drug in combination with radiation and temozolomide or in combination with temozolomide alone.
A Phase II, Open-Label, Multi-Center Study of ANG1005 in Patients with Recurrent High-Grade Glioma
The main purpose of this research study is to see if an investigational drug, ANG1005, can shrink tumor cells in patients with high-grade glioma. Another purpose of this study is to assess the efficacy, safety, tolerability, and pharmacokinetics (PK) of ANG1005 in patients.
A Phase II Trial of Bevacizumab in Patients with Recurrent Solid Tumor Brain Metastases Who Have Failed Whole Brain Radiation Therapy
The purpose of this study is to see what effect bevacizumab, the drug being tested, will have on brain disease from solid tumor cancers. This study will not evaluate the effect of bevacizumab on the systemic solid tumor cancer.
Phase II/III Study of Image-Guided Radiosurgery/SBRT for Localized Spine Metastasis
There are 2 parts to this study (phase II and phase III). The part of the study in which a participant is enrolled depends on the timing of starting in the study. The purpose of the phase II part of the study is to treat the cancer that has spread to a participant's spine, and is causing pain, with image-guided radiosurgery/SBRT. The purpose of phase III is to compare the effects, good and/or bad, of image-guided radiosurgery/SBRT to standard radiation therapy to find out which treatment provides the most rapid pain relief with the least side effects.
Status: Accepting New Patients
Principal Investigator: Kalapurakal
A Phase II Randomized Trial Comparing the Efficacy of Heat Shock Protein-Peptide Complex-96 (HSPPC-96)(NSC #725085, Alliance IND#15380) Vaccine Given with Bevacizumab Versus Bevacizumab Alone in the Treatment of Surgically Resectable Recurrent Glioblastoma Multiforme (GBM)
The purpose of this study is to compare what effects, good and/or bad, a vaccine called HSPPC-96 given with a drug called bevacizumab versus bevacizumab alone has on recurrent glioblastoma multiforme (GBM).
last updated: Fri - January 30, 2015 - 05:58 PM
Clinical trial availability changes frequently. Please check this site often for updates or call 312.695.1102 for personal assistance.